Skip to main content
  • Short DAPT’s Lower Bleeding, Lack of Ischemic Penalty vs. Standard DAPT Continue at 15 Months – MASTER DAPT Follow-Up

    Early de-intensification of antiplatelet therapy in high-bleeding-risk (HBR) patients is associated with lower bleeding and no ischemic penalty at 15 months, despite the allowance of routine care at 1 year, confirming the 12-month results of the MASTER DAPT trial, new findings show.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details